Alzheimer’s diagnostic market to hit $11.82 billion by 2030

By AI, Created 11:01 AM UTC, May 20, 2026, /AGP/ – The Business Research Company says the global Alzheimer’s disease diagnostic market will grow at a 10.3% CAGR to $11.82 billion by 2030, led by North America and the U.S. The report points to blood-based biomarkers, AI tools and personalized diagnostics as major growth drivers.

Why it matters: - Alzheimer’s disease diagnostics are becoming a bigger part of early detection and disease management as health systems push for faster, less invasive testing. - The market’s growth reflects rising demand for biomarker-based tests, neuroimaging, and AI-assisted tools that can improve diagnostic accuracy. - The report estimates the market will reach $11.82 billion by 2030, signaling continued investment in neurodegenerative disease diagnostics.

What happened: - The Business Research Company released its Alzheimer’s Disease Diagnostic Market Report 2026, covering market size, trends and a global forecast through 2035. - The report says the global Alzheimer’s disease diagnostic market will surpass $12 billion in 2030, with a forecast value of $11.82 billion. - The company estimates a 10.3% CAGR for the market over the forecast period. - The report was published April 30, 2026.

The details: - North America is projected to be the largest region in 2030, at $4.6 billion. - North America is expected to grow from $2.9 billion in 2025 at a 10% CAGR. - The U.S. is forecast to be the largest country in the market in 2030, at $4.3 billion. - The U.S. market is projected to rise from $2.7 billion in 2025 at a 10% CAGR. - The diagnosis segment is expected to be the largest by type in 2030, representing 49% of the market, or about $6 billion. - The market is segmented by type into triage, diagnosis and screening. - The market is segmented by diagnostic technique into biomarkers, imaging techniques, genetic testing and cognitive assessment tests. - The market is segmented by end user into clinics, hospitals, diagnostic centers, pharmaceutical companies and academic research centers. - The report says the parent Physicians And Other Health Practitioners market is expected to reach about $2,449 billion by 2030. - The broader Healthcare Services industry is projected at $11,318 billion by 2030. - Alzheimer’s disease diagnostics would represent about 0.5% of the parent market and nearly 0.1% of the broader healthcare services market. - The triage, diagnosis and screening segments are projected to add more than $4 billion in combined market value by 2030. - The report projects the triage market will grow by $1 billion, the diagnosis market by $2 billion and the screening market by $1 billion from 2025 to 2030. - The company also offers a free sample report and a detailed report download through its website: Request a free sample and Access the detailed report.

Between the lines: - The report’s strongest growth themes are non-invasive blood-based biomarkers, personalized medicine and AI-driven diagnostics. - Blood-based biomarker tests are presented as a cheaper and more scalable alternative to cerebrospinal fluid analysis and neuroimaging. - The report says blood-based biomarker development could contribute about 3.0% annual growth to the market. - Personalized medicine and precision diagnostics are projected to contribute about 2.8% annual growth. - AI and machine learning integration are projected to contribute about 2.5% annual growth. - The market outlook suggests diagnostic innovation is shifting toward earlier screening, better patient stratification and more targeted treatment planning. - The report says diagnostic companies are investing in high-sensitivity assays for amyloid-beta and tau proteins. - The report also links market growth to rising awareness, expanding clinical guidelines and stronger reimbursement frameworks.

What’s next: - Growth is expected to continue through 2030 as biomarker testing, neuroimaging and digital tools become more widely adopted. - The report points to expanding use of AI-powered platforms and non-invasive tests as the main forces shaping next-generation Alzheimer’s diagnostics. - Continued clinical trials, drug development activity and research spending in the U.S. and Canada are expected to support demand. - The Business Research Company positions the triage, diagnosis and screening segments as the key areas to watch for future market gains.

The bottom line: - Alzheimer’s diagnostics are moving toward earlier, less invasive and more personalized testing, and the market is projected to more than double by 2030.